Yevgeniy R Semenov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5930653/publications.pdf

Version: 2024-02-01

78 papers

1,765 citations

331259 21 h-index 37 g-index

78 all docs 78 docs citations

78 times ranked 1932 citing authors

#	Article	IF	CITATIONS
1	Bilateral Vestibular Deficiency. JAMA Otolaryngology - Head and Neck Surgery, 2014, 140, 527.	1.2	118
2	Vestibular vertigo and comorbid cognitive and psychiatric impairment: the 2008 National Health Interview Survey. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 367-372.	0.9	110
3	Ethnic differences and comorbidities of 909 prurigo nodularis patients. Journal of the American Academy of Dermatology, 2018, 79, 714-719.e3.	0.6	105
4	Association Between Vestibular and Cognitive Function in U.S. Adults: Data From the National Health and Nutrition Examination Survey. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 243-250.	1.7	102
5	Association Between Visuospatial Ability and Vestibular Function in the Baltimore Longitudinal Study of Aging. Journal of the American Geriatrics Society, 2015, 63, 1837-1844.	1.3	100
6	Evolving phenotypes of non-hospitalized patients that indicate long COVID. BMC Medicine, 2021, 19, 249.	2.3	87
7	Epidural Steroid Injections, Conservative Treatment, or Combination Treatment for Cervical Radicular Pain. Anesthesiology, 2014, 121, 1045-1055.	1.3	81
8	Association of Cutaneous Immune-Related Adverse Events With Increased Survival in Patients Treated With Antiâ \in Programmed Cell Death 1 and Antiâ \in Programmed Cell Death Ligand 1 Therapy. JAMA Dermatology, 2022, 158, 189.	2.0	60
9	Quality of Life and Cost-Effectiveness of Cochlear Implants: A Narrative Review. Audiology and Neuro-Otology, 2017, 22, 236-258.	0.6	58
10	The effect of pneumonia on shortâ€term outcomes and cost of care after head and neck cancer surgery. Laryngoscope, 2012, 122, 1994-2004.	1.1	55
11	Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis. Journal of the American Academy of Dermatology, 2022, 86, 563-572.	0.6	51
12	Age-Dependent Cost-Utility of Pediatric Cochlear Implantation. Ear and Hearing, 2013, 34, 402-412.	1.0	49
13	Healthâ€related quality of life and economic burden of vestibular loss in older adults. Laryngoscope Investigative Otolaryngology, 2018, 3, 8-15.	0.6	44
14	Synchronous primary colorectal and liver metastasis: impact of operative approach on clinical outcomes and hospital charges. Hpb, 2014, 16, 1117-1126.	0.1	43
15	Vestibular Function and Activities of Daily Living. Gerontology and Geriatric Medicine, 2015, 1, 233372141560712.	0.8	41
16	Psoriasis and mortality in the United States: Data from the National Health and Nutrition Examination Survey. Journal of the American Academy of Dermatology, 2021, 85, 396-403.	0.6	39
17	Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA. , 2021, 9, e001935.		38
18	Cochlear Implants. Otolaryngologic Clinics of North America, 2012, 45, 959-981.	0.5	36

#	Article	IF	Citations
19	Health-Related QOL and Economic Burden of Chronic Pruritus. Journal of Investigative Dermatology, 2021, 141, 754-760.e1.	0.3	33
20	The effect of deep venous thrombosis on shortâ€term outcomes and cost of care after head and neck cancer surgery. Laryngoscope, 2012, 122, 2199-2204.	1.1	32
21	Association between vertigo, cognitive and psychiatric conditions in US children: 2012 National Health Interview Survey. International Journal of Pediatric Otorhinolaryngology, 2020, 130, 109802.	0.4	28
22	Health-related quality of life and economic burden of prurigo nodularis. Journal of the American Academy of Dermatology, 2022, 86, 573-580.	0.6	27
23	Constructing germline research cohorts from the discarded reads of clinical tumor sequences. Genome Medicine, 2021, 13, 179.	3.6	25
24	Clinical severity measures and qualityâ€ofâ€life burden in patients with mycosis fungoides and Sézary syndrome: comparison of generic and dermatologyâ€specific instruments. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 995-1003.	1.3	22
25	Cluster Analysis of Circulating Plasma Biomarkers in Prurigo Nodularis Reveals a Distinct Systemic Inflammatory Signature in African Americans. Journal of Investigative Dermatology, 2022, 142, 1300-1308.e3.	0.3	21
26	Postoperative Urinary Tract Infection and Shortâ€Term Outcomes and Costs in Head and Neck Cancer Surgery. Otolaryngology - Head and Neck Surgery, 2013, 148, 602-610.	1.1	20
27	Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. Oncologist, 2021, 26, 514-522.	1.9	18
28	Cutaneous Transcriptomics Identifies Fibroproliferative and Neurovascular Gene Dysregulation in Prurigo Nodularis Compared with Psoriasis and Atopic Dermatitis. Journal of Investigative Dermatology, 2022, 142, 2537-2540.	0.3	18
29	Racial Disparities in the Clinical Presentation and Prognosis of Patients with Mycosis Fungoides. Journal of the National Medical Association, 2019, 111, 633-639.	0.6	17
30	A Nationwide Study of Prurigo Nodularis: Disease Burden and Healthcare Utilization in the United States. Journal of Investigative Dermatology, 2021, 141, 2530-2533.e1.	0.3	17
31	Seasonality of hair loss: a time series analysis of Google Trends data 2004–2016. British Journal of Dermatology, 2018, 178, 978-979.	1.4	16
32	Racial disparities in the management of acne: evidence from the National Ambulatory Medical Care Survey, 2005–2014. Journal of Dermatological Treatment, 2018, 29, 287-289.	1.1	16
33	Healthâ€related quality of life and economic implications of cutaneous Tâ€cell lymphoma. British Journal of Dermatology, 2020, 182, 190-196.	1.4	16
34	The Role of Obliteration in the Achievement of a Dry Mastoid Bowl. Otology and Neurotology, 2015, 36, 1510-1517.	0.7	15
35	Current measures are not sufficient: an interviewâ€based qualitative assessment of quality of life in cutaneous Tâ€cell lymphoma*. British Journal of Dermatology, 2021, 184, 310-318.	1.4	13
36	Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors. Oncologist, 2021, 26, e898-e901.	1.9	12

#	Article	IF	CITATIONS
37	Immunosuppressive biologics did not increase the risk of COVID-19 or subsequent mortality: A retrospective matched cohort study from Massachusetts. Journal of the American Academy of Dermatology, 2022, 86, 252-255.	0.6	12
38	Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses. Journal of Dermatological Treatment, 2022, 33, 1691-1695.	1.1	11
39	Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors. JAMA Dermatology, 2022, 158, 552.	2.0	11
40	Biologics utilization for psoriasis is lower in black compared with white patients. British Journal of Dermatology, 2021, 185, 207-209.	1.4	10
41	Itch in skin of colour: a multicentre crossâ€sectional study. British Journal of Dermatology, 2021, 185, 652-654.	1.4	9
42	Effect of a multidisciplinary Severe Immunotherapy Complications Service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer., 2021, 9, e002886.		9
43	Pre-Existing Autoimmune Disease and Mortality in Patients Treated with Anti-PD-1 and Anti-PD-L1 Therapy. Journal of the National Cancer Institute, 2022, 114, 1200-1202.	3.0	9
44	Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study. Journal of Investigative Dermatology, 2022, 142, 2896-2908.e4.	0.3	9
45	Impaired Vestibular Function and Low Bone Mineral Density: Data from the Baltimore Longitudinal Study of Aging. JARO - Journal of the Association for Research in Otolaryngology, 2016, 17, 433-440.	0.9	8
46	Seasonal variation of itch: A study using real-time data from 2004 to 2016. Journal of the American Academy of Dermatology, 2017, 76, 563-564.	0.6	8
47	Racial differences in dysregulation of the renin-angiotensin-aldosterone system in patients with prurigo nodularis. Journal of Dermatological Science, 2022, 105, 130-136.	1.0	8
48	Association between Itch and Cancer in 3836 Pediatric Pruritus Patients at a Tertiary Care Center. Medicines (Basel, Switzerland), 2019, 6, 99.	0.7	6
49	Comorbidities Associated with Granuloma Annulare: A Cross-Sectional, Case-Control Study. Medicines (Basel, Switzerland), 2020, 7, 53.	0.7	6
50	Validation of International Classification of Diseases Tenth Revision code for prurigo nodularis. Journal of the American Academy of Dermatology, 2022, 87, 482-484.	0.6	6
51	Racial disparities in mortality among patients with prurigo nodularis: A multi-center cohort study. Journal of the American Academy of Dermatology, 2022, 86, 487-490.	0.6	5
52	Latent class analysis identification of prurigo nodularis comorbidity phenotypes. British Journal of Dermatology, 2022, 186, 903-905.	1.4	5
53	Association Between Psoriasis with Arthritis and Hearing Impairment in US Adults: Data from the National Health and Nutrition Examination Survey. Journal of Rheumatology, 2019, 46, 587-594.	1.0	4
54	Racial and ethnic disparities in inpatient health care utilization for mycosis fungoides: A cross-sectional analysis of the 2012-2017 National Inpatient Sample. Journal of the American Academy of Dermatology, 2022, 86, 1408-1410.	0.6	4

#	Article	IF	CITATIONS
55	Racial and socioeconomic differences in acral lentiginous melanoma outcomes: A Surveillance, Epidemiology, and End Results analysis. Journal of the American Academy of Dermatology, 2022, 87, 866-867.	0.6	4
56	An Observational Study on the Molecular Profiling of Primary Melanomas Reveals a Progression Dependence on Mitochondrial Activation. Cancers, 2021, 13, 6066.	1.7	4
57	Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma. Journal of the American Academy of Dermatology, 2022, 87, 1147-1149.	0.6	4
58	A cross-sectional analysis of trends in dermatology practice size in the United States from 2012 to 2020. Archives of Dermatological Research, 2023, 315, 223-229.	1.1	4
59	Risk of Hematologic Cancer in Patients With Undifferentiated Pruritus. JAMA Dermatology, 2022, 158, 791.	2.0	4
60	Food and drug administration approval process for dermatology drugs in the United States. Journal of Dermatological Treatment, 2018, 29, 536-538.	1.1	3
61	Ethnic variations in scalp pruritus and hair loss. Journal of the American Academy of Dermatology, 2021, 84, 792-794.	0.6	3
62	Worldwide seasonal variation in search volume for cutaneous warts from 2004 to 2019. Journal of the American Academy of Dermatology, 2021, 84, 1417-1419.	0.6	3
63	27645 Health-related quality of life and economic burden of prurigo nodularis. Journal of the American Academy of Dermatology, 2021, 85, AB38.	0.6	3
64	Health-related quality of life in patients with malignant melanoma by stage and treatment status. Journal of the American Academy of Dermatology, 2021, 85, 486-489.	0.6	2
65	Proteomic and Phosphoproteomic Analysis Reveals that Neurokinin-1 Receptor (NK1R) Blockade with Aprepitant in Human Keratinocytes Activates a Distinct Subdomain of EGFR Signaling: Implications for the Anti-Pruritic Activity of NK1R Antagonists. Medicines (Basel, Switzerland), 2019, 6, 114.	0.7	2
66	Risk of cancer in psoriasis: study of a nationally representative sample of the US population with comparison to a singleâ€institution cohort. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e529-e531.	1.3	2
67	Evaluating patterns of co-occurrence between cutaneous and noncutaneous immune-related adverse events after immune checkpoint inhibitor therapy. Journal of the American Academy of Dermatology, 2023, 88, 246-249.	0.6	2
68	Diagnostic concordance of clinical diagnosis, tissue culture, and histopathology testing for skin and soft tissue infections: A single-center retrospective study. International Journal of Women's Dermatology, 2020, 6, 395-398.	1.1	1
69	Understanding racial disparities in prurigo nodularis. Journal of the American Academy of Dermatology, 2022, 87, e111-e112.	0.6	1
70	Surgical Outcomes and Risk Factors for Apical Triangle Basal Cell Carcinomas: A Single Institution Analysis. Dermatologic Surgery, 2021, 47, 1125-1127.	0.4	0
71	Patients with steroid-refractory toxicity following immune checkpoint inhibitors: Frequent hospitalizations and long duration of illness Journal of Clinical Oncology, 2021, 39, 2655-2655.	0.8	0
72	Impact of cancer type on the incidence of cutaneous toxicities after immune checkpoint inhibitor therapy: A population-level analysis Journal of Clinical Oncology, 2021, 39, e14553-e14553.	0.8	0

#	Article	IF	CITATIONS
73	Impact of multidisciplinary severe immunotherapy complication service on outcomes for cancer patients receiving immune checkpoint inhibition Journal of Clinical Oncology, 2021, 39, 2654-2654.	0.8	0
74	804â€Real-world incidence and impact of pneumonitis in lung cancer patients treated with immune checkpoint inhibitors. , 2021, 9, A841-A841.		0
75	855â€Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses. , 2020, , .		O
76	Reply to: COVID-19 vaccination in IMID patients receiving rituximab: a personalized regimen should be formulated. Journal of the American Academy of Dermatology, 2022, , .	0.6	0
77	Title: Immune-checkpoint inhibitor therapy is underutilized in the US: A multi-institutional cohort analysis. Immunology Letters, 2022, 244, 43-44.	1.1	0
78	Reduced serum pyridoxine and 25-hydroxyvitamin D levels in adults with chronic pruritic dermatoses. Archives of Dermatological Research, 2022, , 1.	1.1	0